Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial
Open Access
- 19 March 2009
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 69 (01), 113-119
- https://doi.org/10.1136/ard.2008.094623
Abstract
The primary objective was to compare a single, 6 ml, intra-articular injection of hylan G-F 20 with placebo in patients with symptomatic knee osteoarthritis. The safety of a repeat injection of hylan G-F 20 was also assessed. Patients with primary osteoarthritis knee pain were randomly assigned to arthrocentesis plus a 6 ml intra-articular injection of either hylan G-F 20 or placebo in a prospective, double-blind (one injector/one blinded observer) study. Results were evaluated at 4, 8, 12, 18 and 26 weeks post-injection. The primary outcome criterion was change from baseline over 26 weeks in Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index A pain. Secondary outcome measures included WOMAC A1 and C, patient global assessment (PGA) and clinical observer global assessment (COGA) and Outcome Measures in Rheumatology, Osteoarthritis Research Society International responder rates. A 4-week, open, repeat treatment phase evaluated safety only. A total of 253 patients (Kellgren–Lawrence grade II or III) was randomly assigned. Patients receiving hylan G-F 20 experienced statistically significantly greater improvements in WOMAC A pain scores (−0.15, SE 0.076, p = 0.047), and several of the secondary outcome measures (WOMAC A1, PGA and COGA), than patients receiving placebo. There was no difference between the safety results of the two groups. No increased risk of local adverse events was observed in the open, repeat treatment phase. This placebo-controlled study demonstrated that, in patients with knee osteoarthritis, a single 6 ml intra-articular injection of hylan G-F 20 is safe and effective in providing statistically significant, clinically relevant pain relief over 26 weeks, with a modest difference versus placebo. NCT00131352.This publication has 23 references indexed in Scilit:
- Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot studyArchives of orthopaedic and trauma surgery, 2008
- OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelinesOsteoarthritis and Cartilage, 2008
- Viscosupplementation for Knee OsteoarthritisClinical Orthopaedics and Related Research, 2007
- Rheological properties of synovial fluids.2007
- Viscosupplementation for the treatment of osteoarthritis of the kneeEmergencias, 2005
- The Impact of OsteoarthritisClinical Orthopaedics & Related Research, 2004
- EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)Annals Of The Rheumatic Diseases, 2003
- Rheology of joint fluid in total knee arthroplasty patientsJournal of Orthopaedic Research, 2002
- Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 updateArthritis & Rheumatism, 2000
- Rheology of synovial fluid1Biorheology, 1987